10-Q: Skinvisible Reports Q2 2026 Results Amidst Going Concern Doubts

Skinvisible, Inc. filed its Q2 2026 10-Q, revealing continued net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, though progress is noted in licensing and regulatory pathways.

Summary

• Skinvisible, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company experienced a net loss of $255,533 for the three months ended June 30, 2026, and $522,717 for the six months ended June 30, 2026.
• Revenues remained flat at $5,000 for the three-month period and $10,000 for the six-month period, compared to the prior year.
• Operating expenses decreased slightly to $117,817 for the three months and $248,755 for the six months, primarily due to lower selling, general, and administrative costs.
• The company has a substantial working capital deficit of $5,503,128 as of June 30, 2026.
• Management has identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient written policies and procedures.
• There are significant outstanding convertible notes and other payables, with two notes totaling $352,075 and $10,000 in default as of June 30, 2026.
• The company's ability to continue as a going concern is in substantial doubt due to cumulative net losses and the need for future capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to the company's continued net losses, significant working capital deficit, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite some positive developments in licensing and regulatory progress.

Positives

• Revenues remained stable at $5,000 for the three-month period and $10,000 for the six-month period, indicating a consistent, albeit low, revenue stream.
• Operating expenses decreased by approximately 16.6% for the three-month period and 13.1% for the six-month period compared to the prior year, showing cost management efforts.
• The company continues to advance its licensing agreements, particularly with Quoin Pharmaceuticals for QRX003, which has received multiple regulatory designations (Fast Track, Orphan Drug, Rare Pediatric Disease) and is progressing through clinical trials.
• Progress is being made on patent applications for transdermal delivery systems for obesity and glucose-controlling agents, with strategic partnerships being pursued.
• The company has no off-balance sheet arrangements as of June 30, 2026.

Negatives

• The company incurred a net loss of $255,533 for the three months ended June 30, 2026, and $522,717 for the six months ended June 30, 2026.
• Total revenues for the six months ended June 30, 2026, were only $10,000, indicating minimal commercial activity.
• The company has a significant working capital deficit of $5,503,128 as of June 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern due to cumulative net losses of $41,532,893 and the need for future capital.
• Two promissory notes, one for $352,075 and another for $10,000, are in default as of June 30, 2026.
• Material weaknesses in internal control over financial reporting have been identified, including inadequate segregation of duties and insufficient written policies and procedures.

Risks

• The company has incurred cumulative net losses of $41,532,893 since its inception and requires capital for its contemplated operational and marketing activities, raising substantial doubt about its ability to continue as a going concern.
• The ability to generate necessary funds through licensing or raise additional capital through future issuances of common stock or debt is unknown.
• The success of the company is dependent on the successful development of its contemplated plan of operations and its transition to profitable operations.
• There are risks related to failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Uncertainty with respect to intellectual property rights, protecting those rights and claims of infringement of others' intellectual property.
• Competition in the skincare, dermatology, and other healthcare/medical markets.
• Cybersecurity concerns.

Future Outlook

The company hopes to generate more revenues from its licenses with Quoin and Ovation in 2026 and plans to enter into commercial arrangements with pharma and biotech companies to exploit its recent patent applications. Management expects operating expenses to increase as licensing revenue grows. However, the company's ability to continue as a going concern is in substantial doubt, and future operations are dependent on securing additional financing and achieving profitability.

Management Comments

• The Company has incurred cumulative net losses of $41,532,893 since its inception and requires capital for its contemplated operational and marketing activities to take place.
• The Company's ability to generate the necessary funds through licensing of its core products or the ability to raise additional capital through the future issuances of common stock or debt is unknown.
• The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations.
• Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months.
• We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional capital.

Industry Context

StockSavvy.ai notes that Skinvisible operates in the highly competitive global skincare and dermatology market, estimated at $80 billion, and the $30 billion over-the-counter market. The company's strategy of out-licensing its patented Invisicare technology to established manufacturers and marketers aligns with industry trends where pharmaceutical companies increasingly rely on external R&D for new products due to downsizing internal R&D departments. The focus on topical and transdermal solutions for various medical markets, including obesity and pain management, taps into growing areas of pharmaceutical innovation.

Comparison to Industry Standards

• Skinvisible's revenue of $10,000 for the first six months of 2026 is significantly below industry standards for companies with patented technologies in the multi-billion dollar skincare and pharmaceutical markets.
• The company's net loss of $522,717 for the same period, coupled with a substantial working capital deficit, indicates a financial performance far below that of established players in the pharmaceutical and cosmetic industries.
• While progress is noted in regulatory designations for QRX003, the timeline to market and potential revenue generation from this product is still uncertain, contrasting with the more predictable revenue streams of mature industry competitors.
• The company's reliance on future financing and the explicit statement of substantial doubt about its going concern status are critical deviations from industry norms where companies with viable products typically have secured funding or established revenue streams.

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceeding.
• The company is not aware of any pending legal proceeding to which any of its officers, directors, or any beneficial holders of 5% or more of its voting securities are adverse to it or have a material interest adverse to it.

Related Party Transactions

• Loans from related party totaled $128,445 as of June 30, 2026, an increase from $45,044 as of December 31, 2025.
• Due from related party remained constant at $17,592 as of June 30, 2026, and December 31, 2025.
• Convertible notes payable related party totaled $5,372,403 as of June 30, 2026, and December 31, 2025.

Stakeholder Impact

• Shareholders: Continued net losses and the going concern doubt pose significant risks to shareholder value. Potential future equity financing could dilute existing shareholdings.
• Creditors: The company has two notes in default as of June 30, 2026, indicating potential distress for creditors.
• Employees: The company's financial instability and identified control weaknesses may create an uncertain work environment. Remediation efforts for internal controls are dependent on securing financing, which could impact resource allocation for employee-related functions.
• Suppliers: While not explicitly detailed, the company's precarious financial situation could impact its ability to meet payment obligations to suppliers.

Next Steps

• Implement changes to enhance and improve the design of internal controls over financial reporting, including appointing additional qualified personnel and adopting sufficient written policies and procedures.
• Secure additional financing through a private equity offering to fund operations.
• Continue to pursue licensing revenue from agreements with Quoin and Ovation.
• Enter into commercial arrangements with pharma and biotech companies to exploit patent applications for transdermal delivery systems.
• Advance QRX003 through clinical trials and regulatory approval processes with Quoin Pharmaceuticals.
• Pursue strategic partnerships for the application of its delivery platform across diverse disease domains, particularly for obesity and glucose-controlling agents.

Key Dates

Recommendation

The filing indicates significant financial distress, including substantial net losses, a large working capital deficit, and explicit doubt about the company's ability to continue as a going concern. While there are some positive developments in licensing and regulatory progress, these are overshadowed by the immediate financial risks and the lack of clear revenue generation. The need for further capital raises, with no assurance of success, further exacerbates the risk profile for investors.

Keywords

Invisicare, topical delivery system, pharmaceutical, dermatology, licensing, Netherton Syndrome, QRX003, transdermal delivery